Hypertension And Vascular Disorders

Historical Context & Motivation

Hypertension has been recognized as a major contributor to cardiovascular morbidity and mortality for well over a century, yet the understanding of its pathophysiology and optimal management has evolved dramatically. In the early twentieth century, elevated blood pressure was often regarded as a necessary adaptive response—so-called essential hypertension—rather than a disease state requiring treatment. The term 'essential' itself reflected the prevailing belief that increased arterial pressure was 'essential' for adequate end-organ perfusion, particularly in the elderly. This philosophical stance delayed the development of antihypertensive therapy by decades and contributed to enormous cardiovascular morbidity that, in retrospect, was largely preventable.

The central clinical question that has driven over a century of investigation remains highly relevant: At what blood pressure threshold does treatment reduce cardiovascular events, and how aggressively should clinicians pursue those targets? This question frames the entire discussion of hypertension classification, workup, pharmacotherapy, and the recognition of secondary and emergent hypertensive syndromes.

Core Principles & Definitions

The classification and management of hypertension rest on several foundational principles that guide both diagnosis and therapy. Understanding these principles is essential for clinical decision-making and for answering USMLE-style questions that frequently test the distinction between primary and secondary hypertension, appropriate workup triggers, and pharmacologic first-line agents based on patient comorbidities.

Visual Explanation — Blood Pressure Classification & RAAS Pathway

The classification scheme presented in the diagram underscores an important paradigm shift: the 2017 guidelines lowered the threshold for Stage 1 hypertension from 140/90 to 130/80 mmHg. This change was driven primarily by the SPRINT trial, which demonstrated that targeting a systolic blood pressure <120 mmHg in high-risk, non-diabetic patients significantly reduced major cardiovascular events and all-cause mortality compared to the standard target of <140 mmHg. The JNC 8 panel (published 2014) had recommended a more conservative threshold of 140/90 for most adults and 150/90 for patients aged ≥60, but the ACC/AHA guideline now supersedes those recommendations. For Step 2 CK purposes, familiarity with both the 2017 ACC/AHA framework and the general principles underlying JNC recommendations is advisable, as question stems may reference either system.

Pathophysiology & Hemodynamic Framework

The hemodynamic basis of blood pressure is captured by the fundamental relationship between cardiac output and systemic vascular resistance. Understanding this equation is essential for selecting appropriate antihypertensive agents and predicting their physiologic effects, as each drug class targets a different component of this equation.

The renin-angiotensin-aldosterone system (RAAS) is the primary neurohormonal axis targeted in hypertension management. The cascade begins with renin release from juxtaglomerular cells in response to reduced renal perfusion pressure, decreased sodium delivery to the macula densa, or sympathetic β₁-receptor stimulation. Renin cleaves angiotensinogen (produced by the liver) to form angiotensin I, which is then converted to angiotensin II by angiotensin-converting enzyme (ACE), predominantly in the pulmonary vasculature. Angiotensin II exerts potent vasoconstrictive effects, stimulates aldosterone secretion from the adrenal zona glomerulosa (promoting sodium and water retention), triggers ADH release, and promotes vascular smooth muscle hypertrophy. ACE inhibitors, ARBs, and direct renin inhibitors each interrupt this cascade at different levels, while mineralocorticoid receptor antagonists (spironolactone, eplerenone) block the downstream effects of aldosterone.

Secondary Hypertension & Vascular Disorders

Although primary hypertension predominates, identifying secondary hypertension is a high-yield Step 2 topic because these conditions are potentially curable or require specific targeted therapy. Red flags that should prompt secondary workup include onset before age 30, severe or resistant hypertension (uncontrolled on ≥3 drugs including a diuretic), abrupt onset or worsening, hypokalemia without diuretic use, episodic symptoms (palpitations, headache, diaphoresis), abdominal bruit, or significant blood pressure discrepancy between arms.

Key Vascular Disorders Associated with Hypertension

Several vascular disorders are closely intertwined with hypertension, both as consequences and as concurrent conditions. Aortic dissection is perhaps the most dramatic vascular emergency, presenting with sudden-onset, 'tearing' chest or back pain radiating between the scapulae. Stanford Type A dissections (ascending aorta) require emergent surgical repair, whereas Type B dissections (descending aorta) are typically managed medically with IV β-blockers (e.g., esmolol, labetalol) to rapidly reduce heart rate and blood pressure. The initial target is a heart rate <60 bpm and SBP 100–120 mmHg within the first 20 minutes. Peripheral arterial disease (PAD) manifests as claudication, reduced ankle-brachial index (ABI <0.9), and in severe cases, critical limb ischemia. Hypertension is a major modifiable risk factor, and ACE inhibitors have demonstrated particular benefit in PAD patients (HOPE trial). Abdominal aortic aneurysm (AAA) screening with ultrasound is recommended for men aged 65–75 who have ever smoked. Hypertension accelerates aneurysmal growth, and blood pressure control is a cornerstone of conservative management for aneurysms <5.5 cm.

Worked Clinical Example

The following clinical vignette demonstrates the systematic approach to evaluating and managing a patient who presents with hypertension and features suggestive of a secondary cause—a frequently tested scenario on USMLE Step 2 CK.

Antihypertensive Pharmacotherapy: Comparison & Selection

The selection of antihypertensive therapy depends on the patient's comorbidities, race/ethnicity, age, and compelling indications. The following table summarizes the major first-line drug classes, their mechanisms, primary indications, and notable adverse effects—all high-yield for Step 2 CK.

Hypertensive Emergencies & Special Populations

Hypertensive emergencies require rapid but controlled blood pressure reduction to prevent further end-organ damage while avoiding hypotension-induced ischemia. The specific IV agent and target BP depend on the clinical scenario. Understanding these distinctions is critical for Step 2, as question stems often test the appropriate selection of parenteral agents and target reduction rates.

For Step 2, it is equally important to recognize when NOT to aggressively lower blood pressure. In acute ischemic stroke, permissive hypertension is maintained because the ischemic penumbra depends on collateral perfusion driven by elevated arterial pressure. Rapidly lowering BP in this setting can convert a reversible ischemic penumbra into infarction. The exception is when thrombolytic therapy (tPA) is planned—BP must be <185/110 to reduce bleeding risk. In contrast, acute hemorrhagic stroke benefits from early SBP reduction to ~140 mmHg (INTERACT2 trial), as elevated pressure drives continued bleeding and hematoma expansion.

Practice Problems

Lesson Summary